Table 1 Demographic data of all patients
Variables | Value | |||
|---|---|---|---|---|
Total (n = 154) | Cancer (n = 59) | No cancer (n = 95) | p-value | |
Age at MRI (years), mean (SD) | 66.70 (7.15) | 68.61 (7.25) | 65.50 (6.86) | 0.008 |
Comorbidities, n (%) | 81 (52.60) | 30 (50.85) | 51 (53.68) | 0.732 |
Diabetic mellitus | 20 (12.99) | 12 (20.34) | 8 (8.42) | 0.032 |
Hypertension | 28 (18.18) | 15 (25.42) | 13 (13.68) | 0.066 |
Heart disease | 7 (4.55) | 4 (6.78) | 3 (3.16) | 0.429 |
Dyslipidemia | 19 (12.34) | 8 (13.56) | 11 (11.58) | 0.716 |
Cerebrovascular disease | 12 (7.79) | 4 (6.78) | 8 (8.42) | > 0.999 |
Others | 42 (27.27) | 17 (28.81) | 25 (26.32) | 0.735 |
Serum PSA levels (ng/ml) | ||||
Median, IQR | 10.46 (7.10–20.07) | 14.00 (9.58–45.13) | 9.30 (6.49–13.79) | < 0.001 |
< 4 ng/ml, n (%) | 3 (1.95) | 0 (0.00) | 3 (3.16) | |
4–10 ng/ml, n (%) | 68 (44.16) | 18 (30.51) | 50 (52.63) | |
> 10 ng/ml, n (%) | 83 (53.90) | 41 (69.49) | 42 (44.21) | |
Prostate volume (cm3) | ||||
Median (IQR) | 56.98 (37.49–76.40) | 46.99 (32.28–63.92) | 62.41 (40.60–79.79) | 0.016 |
PSAD, median (IQR) | 0.21 (0.12–0.42) | 0.31 (0.19–0.94) | 0.16 (0.10–0.26) | < 0.001 |
Gleason score, n (%) | ||||
2 + 3 = 5 | 2 (3.64) | |||
3 + 3 = 6 | 16 (29.09) | |||
3 + 4 = 7 | 16 (29.09) | |||
4 + 3 = 7 | 8 (14.55) | |||
4 + 4 = 8 | 4 (7.27) | |||
4 + 5 = 9 | 4 (7.27) | |||
5 + 4 = 9 | 4 (7.27) | |||
5 + 5 = 10 | 1 (1.82) | |||